Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MOB.ST
- Price
- 7.74
- Stock movement up
- +0.67 (9.40%)
- Company name
- Moberg Pharma AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 361.41M
- Ent value
- 69.06M
- Price/Sales
- 37.63
- Price/Book
- 0.39
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -78.46%
- 3 year return
- -24.82%
- 5 year return
- -37.55%
- 10 year return
- -30.05%
Last updated: 2025-04-15
DIVIDENDS
MOB.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 37.63 |
| Price to Book | 0.39 |
| EV to Sales | 7.19 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 46.69M |
| EPS (TTM) | -0.38 |
| FCF per share (TTM) | -2.41 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.60M |
| Gross profit (TTM) | 6.19M |
| Operating income (TTM) | -25.12M |
| Net income (TTM) | -18.25M |
| EPS (TTM) | -0.38 |
| EPS (1y forward) | -0.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 64.48% |
| Operating margin (TTM) | -261.54% |
| Profit margin (TTM) | -190.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 308.96M |
| Net receivables | 0.00 |
| Total current assets | 320.98M |
| Goodwill | 0.00 |
| Intangible assets | 587.25M |
| Property, plant and equipment | 0.00 |
| Total assets | 945.32M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 3.67M |
| Total current liabilities | 14.26M |
| Total liabilities | 16.62M |
| Shareholder's equity | 928.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -26.99M |
| Capital expenditures (TTM) | 88.24M |
| Free cash flow (TTM) | -115.23M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -1.97% |
| Return on Assets | -1.93% |
| Return on Invested Capital | -1.96% |
| Cash Return on Invested Capital | -12.39% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.09 |
| Daily high | 7.88 |
| Daily low | 7.09 |
| Daily Volume | 71K |
| All-time high | 457.68 |
| 1y analyst estimate | 19.00 |
| Beta | 0.78 |
| EPS (TTM) | -0.38 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| MOB.ST | S&P500 | |
| Current price drop from All-time high | -98.31% | -12.04% |
| Highest price drop | -99.10% | -56.47% |
| Date of highest drop | 24 Jul 2023 | 9 Mar 2009 |
| Avg drop from high | -52.22% | -11.07% |
| Avg time to new high | 67 days | 12 days |
| Max time to new high | 1373 days | 1805 days |
COMPANY DETAILS
Marketcap
361.41M
Marketcap category
Small-cap
Description
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Employees
10
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Moberg Pharma AB (OMX: MOB) and Allderma today announce that the launch of Terclara® (MOB-015) is ongoing in Norway. The launch marks an important step in both companies' commercial strategy and build...
February 3, 2025
Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The...
December 10, 2024
Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results
September 13, 2024
Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus....
September 13, 2024
("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million...
June 24, 2024
Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has today received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, ...
June 11, 2024